SGC3027 is primarily utilized in the field of cancer research, specifically targeting certain types of cancers that are resistant to conventional therapies. It functions by inhibiting specific enzymes or proteins that are crucial for the survival and proliferation of cancer cells. This makes it a promising candidate for developing new treatments for hard-to-treat malignancies. Researchers are also exploring its potential in combination therapies, where it could enhance the effectiveness of existing drugs. Additionally, its mechanism of action is being studied to understand its broader applicability in other diseases characterized by abnormal cell growth.